Please login to the form below

Not currently logged in
Email:
Password:

fasiglifam

This page shows the latest fasiglifam news and features for those working in and with pharma, biotech and healthcare.

Takeda drops prostate cancer drug in phase III

Takeda drops prostate cancer drug in phase III

The Japanese company also dropped diabetes candidate fasiglifam earlier this year, but it has a good crop of other products at, or nearing, commercialisation.

Latest news

  • Omontys terminal as Takeda switches off support Omontys terminal as Takeda switches off support

    Meanwhile, Takeda has had a bad run of luck with its late-stage pipeline of late, dropping diabetes candidate fasiglifam earlier this year.

  • Takeda pipeline hit by fasiglifam failure Takeda pipeline hit by fasiglifam failure

    Takeda pipeline hit by fasiglifam failure. Diabetes candidate had been set for a 2015 launch. ... Takeda has suffered a major pipeline setback after deciding to terminate development of fasiglifam, a candidate therapy for diabetes that had been scheduled

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Shanghai
Biopharma's Future: Made in China
The world’s second biggest pharma market is entering a new growth phase – but meeting its needs takes investment and expertise...
Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....

Infographics